12th May 2016 BSBMT Scientific Day


Presentations now available with permissions. More to follow..

Session 1: CHECKPOINT BLOCKADE

– Targeting immune regulation at the tumour site – Dr Sergio Quezada, UCL Cancer Institute, London

– Immune checkpoint blockade in solid tumours – Dr James Larkin, Royal Marsden Hospital, London

– Immune checkpoint blockade with ipilimumab in patients with haematologic malignancies who relapse after allogeneic haematopoietic cell transplantation – Dr Matthew Davids , Dana Faber Cancer Institute, Boston

– The evolving role of stem cell transplant and checkpoint inhibition and other novel therapies in NHL – Dr Patrick Jonhston, Mayo Clinic, Minnesota

Session 2: BSBMT Open Meeting

President’s Report – Dr Charles Crawley
CTC Report – Charles Crawley on behalf of Andy Peniket
Treasurer’s Report – Dr Fiona Dignan
Data Registry Report – Mrs Keiren Kirkland

Session 3:The John Goldman Abstract Prize

Identification of mutatations prognostic of relapse after allogeneic transplantation and novel clone emergence at disease recurrence: implications for strategies to prevent post transplant relapseDr Paul Ferguson, Queen Elizabeth Hospital

– Targeting the TCR-beta-constant region for diagnosis and treatment of T-cell malignancies- Dr Paul Maciocia, University College London

– Phase I/II trial in high-risk paediatric patients post allogeneic haematopoietic stem cell transplant (HSCT) treated with ex vivo expanded donor derived adenovirus-specific T cells – Dr Dr Juliana Silva, GOSH

An operational definition of primary refractory acute myeloid leukaemia which allows early identification of patients who may benefit from allogeneic stem cell transplantationDr Paul Ferguson, Queen Elizabeth Hospital Abstract Prize Winner!

Haploidentical BMT with a post-infusion of stem cells cyclophosphamide approach is feasible and leads to a high rate of donor engraftment in haemoglobinopathies allowing universal application of transplantationDr Viaml Kumar, St Mary’s Hospital

Impact of conditioning regimen on outcomes for children with acute myeloid leukaemia transplanted in first complete remissionDr Giovanna Lucchini, GOSH

Session 4

– Defining measurable residual disease in AML and using it for therapeutic decisions – challenges and prospects- Dr Sylvie Freemen, University of Birmingham